ideology-health
  • Our Solutions
  • About Us
    • ideology-health
    Privacy Policy
    Terms of Service
    Inc. 5000

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    Dr. Laura van ‘t Veer describes the residual cancer burden with ctDNA in breast cancer (Video 3/3)
    Sign up to watch this video

    Free access to all Sound Bites content

    Dr. Laura van ‘t Veer describes the residual cancer burden with ctDNA in breast cancer (Video 3/3)

    Published Aug 31, 2026

    L

    Laura van 't Veer, PhD

    Medical Professional

    ctDNA and RCB

    More in this series: ctDNA in Breast Cancer iSpy 2026
    Dr. Laura van ‘t Veer discusses baseline ctDNA as a predictive marker in neoadjuvant breast cancer (Video 1/3)

    Dr. Laura van ‘t Veer discusses baseline ctDNA as a predictive marker in neoadjuvant breast cancer (Video 1/3)

    ctDNA Baseline

    Laura van 't Veer, PhD
    Breast Cancer
    Dr. Laura van ‘t Veer reviews ctDNA clearance at week 3 as an early indicator in breast cancer (Video 2/3)

    Dr. Laura van ‘t Veer reviews ctDNA clearance at week 3 as an early indicator in breast cancer (Video 2/3)

    ctDNA Week 3 Indicator

    Laura van 't Veer, PhD
    Breast Cancer
    Related Videos
    Dr. Gabriela Hobbs examines how ropeginterferon moves beyond disease control toward disease modification in the treatment of polycythemia vera. (Video 2/3)

    Dr. Gabriela Hobbs examines how ropeginterferon moves beyond disease control toward disease modification in the treatment of polycythemia vera. (Video 2/3)

    Gabriela Hobbs, MD
    Dr. Eytan Stein reviews the patient impact of treating AML at the first opportunity versus waiting for mutational testing (Video 2/3)

    Dr. Eytan Stein reviews the patient impact of treating AML at the first opportunity versus waiting for mutational testing (Video 2/3)

    Eytan Stein, MD
    Dr. Wade Iams discusses adverse event prophylaxis strategies for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 1/3)

    Dr. Wade Iams discusses adverse event prophylaxis strategies for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 1/3)

    Wade Iams, MD
    What makes ropeginterferon a modern interferon? Dr. Gabriela Hobbs explains. (Video 1/3)

    What makes ropeginterferon a modern interferon? Dr. Gabriela Hobbs explains. (Video 1/3)

    Gabriela Hobbs, MD
    Dr. Eytan Stein discusses durability of treatment in IC-ineligible AML (Video 1/3)

    Dr. Eytan Stein discusses durability of treatment in IC-ineligible AML (Video 1/3)

    Eytan Stein, MD
    Dr. Ghaith Abu-Zeinah discusses when to initiate treatment in essential thrombocythemia (Video 3/3)

    Dr. Ghaith Abu-Zeinah discusses when to initiate treatment in essential thrombocythemia (Video 3/3)

    Ghaith Abu-Zeinah, MD